Patents by Inventor Thomas Caulfield

Thomas Caulfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WNT MODULATORS TO TREAT CENTRAL NERVOUS SYSTEM INJURIES
    Publication number: 20240066038
    Abstract: Provided herein are methods of treating a central nervous system injury by administering a Wnt modulator to a subject suffering therefrom.
    Type: Application
    Filed: January 6, 2022
    Publication date: February 29, 2024
    Inventors: Guojun Bu, Yonghe Li, Thomas Caulfield
  • WNT ACTIVATORS AND METHODS OF USE
    Publication number: 20220267271
    Abstract: Provided herein are compounds of Formula (I): and methods of activating Wnt using compounds as disclosed herein.
    Type: Application
    Filed: July 8, 2020
    Publication date: August 25, 2022
    Inventors: Guojun Bu, Thomas Caulfield, Yonghe Li, Chia-Chen Liu
  • DUAL FLUID CIRCUIT SYSTEM FOR GENERATING A VAPOROUS WORKING FLUID USING SOLAR ENERGY
    Publication number: 20120274069
    Abstract: Systems for producing vaporous working fluid are provided, including: a first fluid passage configured to convey a working fluid to a first solar heating system, wherein the first solar heating system heats the working fluid to produce a heated working fluid having a temperature t1 and a quality X1; a second fluid passage configured to convey a heat transfer fluid to a second solar heating system to produce a heated heat transfer fluid; and a heat exchanger configured to transfer heat from the heated heat transfer fluid to the heated working fluid. When X1<1, the heat transfer results in an increase in quality of the heated working fluid When X1=1, the heat transfer results in an increase in temperature of the heated working fluid. Methods of using the systems to produce vaporous working fluid are also provided.
    Type: Application
    Filed: October 29, 2010
    Publication date: November 1, 2012
    Applicant: AREVA Solar, Inc.
    Inventors: Milton Venetos, Thomas Caulfield, William M. Conlon, Robert Brown Callery
  • CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS
    Publication number: 20090226411
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: December 16, 2008
    Publication date: September 10, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7482352
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: January 27, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
    Publication number: 20070232572
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds and their therapeutic application in humans.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 4, 2007
    Applicants: Aventis Pharma S.A., Centre National De La Recherche Scientifique, Museum National D'Histoire Naturelle, Institut Curie, Commissariat A L'Energie Atomique, Universite De Reims Champagne-Ardenne
    Inventors: Augustin Hittinger, Thomas Caulfield, Patrick Mailliet, Herve Bouchard, Eliane Mandine, Jean-Louis Mergny, Lionel Guittat, Jean-Francois Riou, Dennis Gomez, Chafke Belmokhtar
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7179816
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof
    Publication number: 20050203170
    Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
    Type: Application
    Filed: April 19, 2005
    Publication date: September 15, 2005
    Inventors: Patrick Mailliet, Cecile Combeau, Marie-Christine Bissery, Marie-Pierre Cherrier, Thomas Caulfield, Gilles Tiraboschi
  • Triazine derivatives and their application as antitelomerase agents
    Patent number: 6887873
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-François Riou, Gilles Doerflinger, Jean-Louis Mergny, François Hamy, Thomas Caulfield
  • Substituted arylcycloalkanes, compositions containing them and use thereof
    Patent number: 6887904
    Abstract: Substituted arylcycloalkanes, compositions containing them and use thereof. The present invention relates especially to substituted arylcycloalkanes with therapeutic activity, which may be used such as in oncology.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S. A.
    Inventors: Patrick Mailliet, Marc Capet, Gilles Tiraboschi, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070571
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: November 19, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdekazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070575
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 30, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 6858608
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF
    Publication number: 20040147584
    Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
    Type: Application
    Filed: December 4, 2002
    Publication date: July 29, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Cecile Combeau, Marie-Christine Bissery, Mari-Pierre Cherrier, Thomas Caulfield, Gilles Tiraboschi
  • 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof
    Publication number: 20030153611
    Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
    Type: Application
    Filed: December 4, 2002
    Publication date: August 14, 2003
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick Mailliet, Cacile Combeau, Marie-Christine Bissery, Thomas Caulfield, Gilles Tiraboschi, Marie-Pierre Cherrier
  • Substituted arylcycloalkanes, compositions containing them and use thereof
    Publication number: 20030149072
    Abstract: Substituted arylcycloalkanes, compositions containing them and use thereof. The present invention relates especially to substituted arylcycloalkanes with therapeutic activity, which may be used such as in oncology.
    Type: Application
    Filed: December 4, 2002
    Publication date: August 7, 2003
    Inventors: Patrick Mailliet, Marc Capet, Gilles Tiraboschi, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerease agent
    Publication number: 20030087931
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: March 25, 2002
    Publication date: May 8, 2003
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030078263
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: January 9, 2002
    Publication date: April 24, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Solder ball connections and assembly process
    Patent number: 6504105
    Abstract: High melting temperature Pb/Sn 95/5 solder balls are connected to copper pads on the bottom of a ceramic chip carrier substrate by low melting temperature eutectic Pb/Sn solder. The connection is made by quick reflow to prevent dissolving Pb into the eutectic solder and raising its melting temperature. Then the module is placed on a fiberglass-epoxy circuit board with the solder balls on eutectic Pb/Sn solder bumps on copper pads of the board. The structure is reflowed to simultaneously melt the solder on both sides of the balls to allow each ball to center between the carrier pad and circuit board pad to form a more symmetric joint. This process results in structure that are more reliable under high temperature cycling.
    Type: Grant
    Filed: May 1, 1996
    Date of Patent: January 7, 2003
    Assignee: International Business Machines Corporation
    Inventors: John Acocella, Donald Ray Banks, Joseph Angelo Benenati, Thomas Caulfield, Karl Grant Hoebener, David P. Watson, John Saunders Corbin, Jr.
  • Solder ball connections and assembly process
    Patent number: 5675889
    Abstract: Two substrates are produced each with a planar, mirror-image matrix of metal contacts in a surface wiring layer. The substrates are positioned with the matrices in parallel confrontation which defines pairs of confronting contacts. A metal ball is positioned between each pair of contacts with a respective volume of joining material between the ball and each of the two respective contacts. The volumes of joining material are simultaneously melted to allow surface tension to align the substrates and to accurately center the balls between each respective pairs of contacts in a plane defines by the matrix of balls.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignee: International Business Machines Corporation
    Inventors: John Acocella, Donald Ray Banks, Joseph Angelo Benenati, Thomas Caulfield, John Saunders Corbin, Jr., Karl Grant Hoebener, David P. Watson